Ranibizumab (Anti-VEGFA) is a recombinant
humanized IgG1 monoclonal antibody fragment that inhibits (VEGF-A) and degrades
angiogenesis throughout the body and in the eye also interrupts the interaction
of VEGF with its receptors, and thus prevents the subsequent growth of new
blood vessels.
Statement:
->>Products covered by valid patents are not offered or supplied for commercial use.
->>Products currently covered by valid US Patents are offered for laboratory R&D use in accordance with 35 USC 271(e)+A13(1).
->>Any patent infringement and resulting liability is solely at buyer's risk.
->>Our products are only raw materials for drugs or industry, can't be used for human or animals directly.